Elekta highlights ASTRO data showing 37.4% two-year survival in localized pancreatic cancer patients treated on Unity MR-Linac

Bitget2026/09/28 17:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elekta flagged clinical results already presented at ASTRO 2026 on its Unity MR-Linac in localized pancreatic cancer.
The Memorial Sloan Kettering study tracked non-surgical patients, showing durable tumor control with encouraging longer-term survival.
Findings support broader uptake of MR-guided adaptive radiotherapy, a key growth area for Elekta’s high-end radiotherapy franchise.
Elekta is advancing Unity with Unity Pro to speed workflows, aiming to make daily adaptive treatments more practical across centers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elekta AB published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elekta highlights ASTRO data showing 37.4% two-year survival in localized pancreatic cancer patients treated on Unity MR-Linac

You may also like

Crypto prices